These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20567622)

  • 1. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer.
    Lo M; Ling V; Low C; Wang YZ; Gout PW
    Curr Oncol; 2010 Jun; 17(3):9-16. PubMed ID: 20567622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance.
    Lo M; Ling V; Wang YZ; Gout PW
    Br J Cancer; 2008 Aug; 99(3):464-72. PubMed ID: 18648370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
    Guan J; Lo M; Dockery P; Mahon S; Karp CM; Buckley AR; Lam S; Gout PW; Wang YZ
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):463-72. PubMed ID: 19104813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug.
    Gout PW; Buckley AR; Simms CR; Bruchovsky N
    Leukemia; 2001 Oct; 15(10):1633-40. PubMed ID: 11587223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines.
    Pham AN; Blower PE; Alvarado O; Ravula R; Gout PW; Huang Y
    J Pharmacol Exp Ther; 2010 Mar; 332(3):949-58. PubMed ID: 20007406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy.
    Doxsee DW; Gout PW; Kurita T; Lo M; Buckley AR; Wang Y; Xue H; Karp CM; Cutz JC; Cunha GR; Wang YZ
    Prostate; 2007 Feb; 67(2):162-71. PubMed ID: 17075799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
    Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
    Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cystine uptake disrupts the growth of primary brain tumors.
    Chung WJ; Lyons SA; Nelson GM; Hamza H; Gladson CL; Gillespie GY; Sontheimer H
    J Neurosci; 2005 Aug; 25(31):7101-10. PubMed ID: 16079392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The X
    Zheng Z; Luo G; Shi X; Long Y; Shen W; Li Z; Zhang X
    Cell Oncol (Dordr); 2020 Feb; 43(1):95-106. PubMed ID: 31617161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion.
    Sleire L; Skeie BS; Netland IA; Førde HE; Dodoo E; Selheim F; Leiss L; Heggdal JI; Pedersen PH; Wang J; Enger PØ
    Oncogene; 2015 Dec; 34(49):5951-9. PubMed ID: 25798841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB.
    Chung WJ; Sontheimer H
    J Neurochem; 2009 Jul; 110(1):182-93. PubMed ID: 19457125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells.
    Narang VS; Pauletti GM; Gout PW; Buckley DJ; Buckley AR
    Anticancer Res; 2003; 23(6C):4571-9. PubMed ID: 14981898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of xc⁻ transporter-mediated cystine uptake by sulfasalazine analogs.
    Shukla K; Thomas AG; Ferraris DV; Hin N; Sattler R; Alt J; Rojas C; Slusher BS; Tsukamoto T
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6184-7. PubMed ID: 21889337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma.
    Nagane M; Kanai E; Shibata Y; Shimizu T; Yoshioka C; Maruo T; Yamashita T
    PLoS One; 2018; 13(4):e0195151. PubMed ID: 29649284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc
    Guo W; Li K; Sun B; Xu D; Tong L; Yin H; Liao Y; Song H; Wang T; Jing B; Hu M; Liu S; Kuang Y; Ling J; Li Q; Wu Y; Wang Q; Yao F; Zhou BP; Lin SH; Deng J
    Cancer Res; 2021 Feb; 81(3):552-566. PubMed ID: 33229341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine.
    Gout PW; Simms CR; Robertson MC
    Anticancer Drugs; 2003 Jan; 14(1):21-9. PubMed ID: 12544255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases.
    Lo M; Wang YZ; Gout PW
    J Cell Physiol; 2008 Jun; 215(3):593-602. PubMed ID: 18181196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer.
    Kim EH; Shin D; Lee J; Jung AR; Roh JL
    Cancer Lett; 2018 Sep; 432():180-190. PubMed ID: 29928961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular Concentration of L-Cystine Determines the Sensitivity to System x
    Abdullah M; Lee SJ
    Biomol Ther (Seoul); 2022 Mar; 30(2):184-190. PubMed ID: 34667132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
    Roh JL; Kim EH; Jang HJ; Park JY; Shin D
    Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.